Tiziana Life Sciences (Tiziana Life Sciences) Debt-to-Equity : 0.03 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tiziana Life Sciences Debt-to-Equity?

Tiziana Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.17 Mil. Tiziana Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.18 Mil. Tiziana Life Sciences's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $13.30 Mil. Tiziana Life Sciences's debt to equity for the quarter that ended in Jun. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Tiziana Life Sciences's Debt-to-Equity or its related term are showing as below:

TLSA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.2 Med: 0.03 Max: 1.63
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Tiziana Life Sciences was 1.63. The lowest was -0.20. And the median was 0.03.

TLSA's Debt-to-Equity is ranked better than
82.16% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs TLSA: 0.03

Tiziana Life Sciences Debt-to-Equity Historical Data

The historical data trend for Tiziana Life Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tiziana Life Sciences Debt-to-Equity Chart

Tiziana Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

-0.15

0.01

0.02

Tiziana Life Sciences Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															0.02	-	-	0.02	0.03

Competitive Comparison of Tiziana Life Sciences's Debt-to-Equity

For the Biotechnology subindustry, Tiziana Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tiziana Life Sciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tiziana Life Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Tiziana Life Sciences's Debt-to-Equity falls into.

Tiziana Life Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Tiziana Life Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.122	+	0.243)	/	19.571
	=	0.02

Tiziana Life Sciences's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.17	+	0.183)	/	13.295
	=	0.03

Tiziana Life Sciences (NAS:TLSA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Tiziana Life Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Tiziana Life Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tiziana Life Sciences (Tiziana Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tiziana Life Sciences Ltd (NAS:TLSA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0RP:Germany

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM 11

Website

https://www.tizianalifesciences.com

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.